Back

All diabetic patients should be treated with SGLT2 inhibitors.

29 August 2022 (09:06 - 09:24)
Organised by:
Congress Presentation Part of: Meet the Experts: how to lower cardiovascular disease risk in patients with diabetes Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Associate Professor Linda Mellbin

Karolinska University Hospital, Stockholm (Sweden)

4 More presentations in this session

Presentation thumbnail
Assessment of risk in diabetic patients.
Professor F. Cosentino (Stockholm, SE)
Slides Video
Presentation thumbnail
All diabetic patients should be treated with GLP1 and/or GIP agonists.
Professor A. Cahn (Jerusalem, IL)
Slides Video
Presentation thumbnail
All diabetic patients should be treated with metformin.
Professor H. Drexel (Feldkirch, AT)
Slides Video
Presentation thumbnail
Putting it all together: how to lower cardiovascular disease risk in patients with diabetes.
Professor N. Marx (Aachen, DE)
Slides Video

Access the full session

Session thumbnail
Meet the Experts: how to lower cardiovascular disease risk in patients with diabetes
Video

The Event

Event poster

ESC Congress 2022

29 August 2022 09:06 CET
You may be interested in
thumbnail
Congress Presentation
A broader benefit: from heart failure to wider cardio-renal-metabolic (CRM) conditions
31 August 2024
thumbnail
Congress Presentation
Anti-diabetes therapy beyond glycaemic control
31 August 2024
thumbnail
Congress Presentation
Beneficial effects of SGLT2 inhibitors in patients with heart failure and kidney disease – What and why?
22 May 2023
thumbnail
Congress Presentation
The patient with T2DM and CKD: how to screen, how to manage
26 April 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources